We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Discusses More ESA Labeling Updates With FDA
Amgen Discusses More ESA Labeling Updates With FDA
December 21, 2007
Amgen is in discussions with the FDA to update physician labeling for its erythropoiesis stimulating agents (ESAs) Aranesp and Epogen to reflect new safety data from two clinical trials.